Brought to you by Nuclear Education Online (NEO)                    Volume 2, No. 6               July 2004

NeutroSpec Receives FDA Approval
Palatin Technologies, Inc. has received full approval from the FDA to market NeutroSpec™, indicated for the diagnosis of appendicitis in patients with equivocal signs. NeutroSpec will be marketed and distributed Mallinckrodt Imaging.  Click here to review the package insert.
Stark II Still Allows for In-Office Radiology Services
In late March, the Centers for Medicare and Medicaid Services published Phase II of the Stark II rules, a new set of physician self-referral restrictions that take effect July 26.  The fundamental premise of Stark is this: If a physician or a member of a physician's immediate family has a financial relationship with a healthcare facility, the physician may not refer Medicare or Medicaid patients to that facility for designated health services such as radiology unless an exception applies.  Nuclear medicine is excluded from the Stark legislation.  For more information...
Holmium-166 DOTMP
NeoRx has filed an investigational new drug (IND) application with the FDA for a phase II clinical study of its Skeletal Targeted Radiotherapy (STR) Ho-166 DOTMP in patients with breast cancer that has metastasized to the bone. After injection Ho-166 DOTMP rapidly binds to bone mineral, delivering a brief, intense dose of radiation to destroy cancer cells in the bone and marrow For more information....
Comments or Suggestions?  Let us know your thoughts about the newsletter.

Aug. 1 BCNP Exam Registration Deadline
Sept. 4-9 FIP Annual Meeting, New Orleans, LA
Sept. 4-8 European Nuclear Medicine Meeting, Helsinki, Finland
Sept. 9-12 Third Annual Meeting of the Society for Molecular Imaging
St. Louis, Missouri
Sept. 10-12 Southeastern Chapter Meeting
Clearwater Beach, Florida
Sept. 30-Oct 2 ASNC Annual Meeting, Clearwater, FL

 If this email does not view graphics properly go to

Brought to you by

© 2004 Nuclear Education Online
4301 W. Markham #522
Little Rock, AR  72205
For more information, contact Nicki Hilliard

The three-bladed radiation warning symbol, as we currently know it, was "doodled" out at the University of California Radiation Laboratory in Berkeley sometime in 1946 by a small group of people. "A number of people in the group took an interest in suggesting different motifs, and the one arousing the most interest was a design which was supposed to represent activity radiating from an atom."

The first signs printed at Berkeley had a magenta  symbol on a blue background. The magenta was selected because "it was distinctive and did not conflict with any color code that we were familiar with. Another factor in its favor was its cost. . . The high cost will deter others from using this color promiscuously." The original blue background was later changed to yellow for visibility. For more information about the history of the radiation symbol click here.

The patient is a 31 year old white female who presented with right upper quadrant and epigastric pain. She had several days of persistent pain from right breast to her right side.  Continued....

To subscribe to this mailing list click here.